Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative Colitis
William J. Sandborn(University of San Diego), Paul Rutgeerts(KU Leuven), Peter R. Gibson(Monash University), Jean‐Frédéric Colombel(Mount Sinai Hospital), Toshifumi Hibi∥(Kitasato Institute Hospital), Brian G. Feagan(Western University), Gunnar Järnerot(Örebro University Hospital), Colleen Marano(Johnson & Johnson (United States)), Cynthia Guzzo(Janssen (Belgium)), Judith Collins(Oregon Health & Science University), Walter Reinisch(Medical University of Vienna), Jewel Johanns(Johnson & Johnson (United States)), Richard Strauß(Hennepin County Medical Center), Hongyan Zhang(Northwest A&F University), Omoniyi J. Adedokun(Western University)
Cited by 938
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
|Nature Genetics|2008|2.6k